TDO2 and neoplasm: Diaryl hydroxylamines have emerged as promising scaffolds for targeting the tryptophan-catabolizing enzymes indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), key drivers of tumor immune escape.